

What is the Role of Buprenorphine in the Era of Abuse Deterrent Formulations?

Poster
#31

By the NEMA Research Group: Joseph V. Pergolizzi, Jr., MD;¹ Peter Magnusson, MD;^{2,3} Jo Ann LeQuang, BA;¹ Charles Wollmuth;¹ Robert Taylor, Jr., PhD;¹ Rohit Nalamasu, DO;⁴ Kailyn Mitchell, MD;¹ Frank Breve, PharmD⁵ and Giustino Varrassi, MD⁶



¹NEMA Research, Inc., Naples, Florida, United States of America ²Department of Medicine, Cardiology Research Unit, Karolinska Institutet, Stockholm, Sweden ³Centre for Research and Development, Region Gävleborg/Uppsala University, Gävle, Sweden ⁴Department of Physical Medicine and Rehabilitation, University of Nebraska Medical Center, Omaha, Nebraska, United States of America ⁵Department of Pharmacy Practice, School of Pharmacy, Temple University, Philadelphia, Pennsylvania, United States of America ⁶Paolo Procacci Foundation, Rome, Italy

ABSTRACT

- The role of opioids in chronic pain management is controversial. Opioids are associated with a number of potentially treatment-limiting adverse effects, such as opioid-induced constipation and somnolence; can cause dependence; and may lead to use disorder in certain individuals. Nevertheless, they are effective analgesics. To help reduce opioid use disorder and related morbidity and mortality, abuse-deterrent formulations (ADFs) have been introduced to the market along with other measures to reduce opioid use disorder while still providing analgesic benefits. The Food and Drug Administration (FDA) has specifically advocated for the development of ADFs and issued guidance to pharmaceutical companies.^{1,2} Yet ADFs have failed to gain widespread acceptance, possibly because they are more expensive than generic opioid analgesic and are not always reimbursed.
- Buprenorphine was developed in 1966 in England by John Lewis a chemist working for Reckitt & Colman, a home products company. During the 1980s, buprenorphine was offered as a safe, effective pharmacologic therapy for heroin addiction, and the injectable and the sublingual form of the drug were widely used for analgesic purposes by the mid-1980s. In the mid-1990s, countries started approving buprenorphine for the treatment of opioid dependence, starting with France. Subutex[®] and Suboxone[®] were approved in 2002 by the FDA for the treatment of opioid addiction. However, buprenorphine is also an effective analgesic and certain buprenorphine products have been approved for pain indications.³
- In fact, the use of buprenorphine as an analgesic agent offers some interesting advantages. Unlike most strong opioids, which are Schedule II controlled substances, buprenorphine is a Schedule III agent. It has a ceiling effect for respiratory depression and is not as well “liked” by people who seek the psychoactive effects of opioids as other agents, such as oxycodone or hydromorphone. Its available in a transdermal delivery system makes it relatively difficult to tamper with the drug for misuse.
- The authors sought to investigate the role of buprenorphine in the context of ADFs.

METHODS

- This is a narrative review, so the authors searched keywords such as “buprenorphine chronic pain,” “buprenorphine abuse” and “buprenorphine abuse-deterrent formulations.”
- The authors include many who have published on buprenorphine previously, and their expertise as well as clinical opinions were sought. The bibliographies of key articles were also used.

RESULTS

Table 1. Buprenorphine Indications		
Formulation	Route	Indication
Buprenorphine + Naloxone		
Suboxone	Sublingual film	Opioid use disorder
Zubsolv	Sublingual tablet	Opioid use disorder
Bunavail	Buccal film	Opioid use disorder
Buprenorphine		
Subutex	Sublingual tablet	Opioid use disorder
Belbuca	Buccal film	Pain Management
Buprenex	Intravenous	Pain Management
Butrans	Transdermal patch	Pain Management
Probuphine	30-day subcutaneous implant	Opioid use disorder

Adapted from “Velandar JR. Suboxone: Rationale, Science, Misconceptions. *Ochsner J.* 2018;18(1):23-29.

- There are numerous studies reporting on the analgesic effectiveness and safety of buprenorphine in the context of chronic noncancer pain. It has been effective in treating musculoskeletal pain^{4,5} and low back pain.⁶ In a four-arm multicenter study comparing morphine, transdermal fentanyl, transdermal buprenorphine, and oxycodone in 520 cancer pain patients, all agents were similarly effective in controlling pain.⁷ Transdermal buprenorphine was found noninferior to tramadol for postoperative pain control in spinal fusion patients⁸ and was likewise noninferior to co-codamol for osteoarthritis pain⁹ and was similarly effective to hydrocodone/acetaminophen for osteoarthritis pain management.¹⁰
- Yet buprenorphine is not frequently prescribed for pain control. Its development, marketing, promotion, and the breadth of clinical experience with buprenorphine has “type-cast” this agent in the role of a medication to manage opioid use disorder rather than as a pain reliever. Prescribers may be unaware that it is indicated and available for pain control and may be under the impression that in the United States they need a so-called “X-waiver” for substance abuse treatment in order to prescribe buprenorphine in any context, including for pain. Buprenorphine prescribing for pain is regulated by the Drug Enforcement Agency (DEA) in the same manner as oxycodone or morphine prescribing.
- An important advantage in the use of buprenorphine is that it has a proposed ceiling effect for respiratory depression but no ceiling effect for analgesia.^{11,12} Although buprenorphine is sometimes described as a “partial agonist” of the μ -opioid receptors, it may be considered a full agonist in terms of analgesic effect.³
- A further drawback to the use of buprenorphine for treating pain is that it may not be reimbursed as a first-line drug, causing prescribers to select higher-risk Schedule II substances, such as oxycodone, first. If a patient fails on these Schedule II substances, it may be permitted to have the Schedule III buprenorphine product reimbursed, but this requires the exposure of a patient to the Schedule II substance before buprenorphine can be considered. Buprenorphine is effective in the treatment of pain and is less well “liked” by those who seek the psychoactive effects of pain relievers.¹³ It is time to re-imagine and re-evaluate buprenorphine as a pain reliever and to allow it to join the ADFs and other products that may help resist or deter opioid use disorder.

Table 2. Myths about Buprenorphine’s Uses	
FALSE	Buprenorphine does not control pain
FALSE	It is illegal to prescribe buprenorphine
FALSE	Buprenorphine is less potent (“weaker”) than morphine
FALSE	Buprenorphine cannot be combined with full mu agonists
FALSE	Buprenorphine is safe and cannot cause respiratory depression
FALSE	Buprenorphine/naloxone combination has minimal risk of abuse
FALSE	Naloxone in combination with buprenorphine blocks pain control

Adapted from “Arbuck, D. Buprenorphine: A Promising Yet Overlooked Tool. A perspective on why partial agonists such as buprenorphine offer an effective alternative to full opioid agonists. *Practical Pain Management.* 2020; 19(3), 33-38.

CONCLUSIONS

- Buprenorphine has become so well-known and valued for its role in medication-assisted therapy for opioid use disorder that it obscures the fact that it is also a safe, effective pain reliever. Certain buprenorphine products have been approved for pain indications.
- The role of buprenorphine for pain may be overlooked, but could be of vital importance. As an opioid, buprenorphine is not as well “liked” as other opioids by those who seek the psychoactive effects of opioids. It has a proposed ceiling for respiratory depression and tolerability and safety profiles similar to other opioids. It is a Schedule III controlled substance, rather than Schedule II. In clinical trials, buprenorphine has been effective in managing cancer pain as well as chronic noncancer pain.
- As the FDA encourages the development of ADF opioid products, it is time to re-evaluate buprenorphine and expand its reimbursement so that it can be more widely prescribed to appropriate pain patients.

REFERENCE

- FDA. Abuse-deterrent opioid analgesics. Food and Drug Administration. Drugs Web site. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics>. Published 2019. Updated June 11, 2019. Accessed August 26, 2019.
- FDA. Abuse-deterrent opioids-evaluation and labeling. Guidance for industry. Food and Drug Administration. <https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/abuse-deterrent-opioid-analgesics>. Published 2015. Accessed August 26, 2019.
- Pergolizzi J, Aloisi AM, Dahan A, et al. Current knowledge of buprenorphine and its unique pharmacological profile. *Pain Pract.* 2010;10(5):428-450.
- Yoon DH, Bin SI, Chan SK, et al. Effectiveness and tolerability of transdermal buprenorphine patches: a multicenter, prospective, open-label study in Asian patients with moderate to severe chronic musculoskeletal pain. *BMC Musculoskelet Disord.* 2017;18(1):337.
- Leng X, Li Z, Lv H, et al. Effectiveness and Safety of Transdermal Buprenorphine Versus Sustained-release Tramadol in Patients With Moderate to Severe Musculoskeletal Pain: An 8-Week, Randomized, Double-Blind, Double-Dummy, Multicenter, Active-controlled, Noninferiority Study. *Clin J Pain.* 2015;31(7):612-620.
- Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic low back pain: a randomized, double-blind, placebo-controlled crossover study, followed by an open-label extension phase. *Clin Ther.* 2010;32(5):844-860.
- Corli O, Floriani I, Roberto A, et al. Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. *Ann Oncol.* 2016;27(6):1107-1115.
- Kim HJ, Ahn HS, Nam Y, Chang BS, Lee CK, Yeom JS. Comparative study of the efficacy of transdermal buprenorphine patches and prolonged-release tramadol tablets for postoperative pain control after spinal fusion surgery: a prospective, randomized controlled non-inferiority trial. *Eur Spine J.* 2017;26(11):2961-2968.
- Conaghan PG, O’Brien CM, Wilson M, Schofield JP. Transdermal buprenorphine plus oral paracetamol vs an oral codeine-paracetamol combination for osteoarthritis of hip and/or knee: a randomised trial. *Osteoarthritis Cartilage.* 2011;19(8):930-938.

Disclosures: JVP discloses the following relationships: Consultant/ Speaker and Researcher for US World Meds, BMS, Salix, Enalare, Scilex, Pfizer, Lilly, Teva, Regeneron, Redhill, Grunenthal, and Neumentum. The other authors have nothing to disclose.